BIOVICA INTERNATIONAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.706 SEK | +6.36% |
|
-22.81% | -33.88% |
| Apr. 13 | Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024. | CI |
| Apr. 12 | Biovica International AB Announces Divitum® Tka in Observational Trial | CI |
Presentation Operator MessageOperator (Operator)Welcome to the Biovica International Audiocast...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.
Calendar
2024-06-17
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.604
SEK
Average target price
15
SEK
Spread / Average Target
+835.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.88% | 12.36M | |
| -20.32% | 10.67B | |
| +43.79% | 3.22B | |
| -35.74% | 2.09B | |
| -17.21% | 2.04B | |
| -29.37% | 1.46B | |
| +17.94% | 1B | |
| -4.37% | 734M | |
| -36.46% | 391M | |
| -46.12% | 379M |
- Stock Market
- Equities
- BIOVIC B Stock
- News Biovica International AB
- Transcript : Biovica International AB, Q1 2022 Earnings Call, Sep 02, 2021
